ISPC
NASDAQiSpecimen Inc.
iSpecimen Inc. (ISPC) is a Biotechnology: Commercial Physical & Biological Resarch company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for ISPC, including 4 SEC filings, 2 press releases and news items and 1 M&A update. The most recent was published Nov 9, 2026.
Financial highlights
Full financials- Revenue, TTM
- $466.3K
- Revenue growth
- -92.1%
- Net income, TTM
- -$11.42M
- Net margin
- -2449.0%
- Cash
- $4.41M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks34+133%
2026-05-172026-11-08
Mix1890d
- SEC Filings12(67%)
- Other5(28%)
- M&A1(6%)
Activity · 52 weeks7257 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECiSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - iSpecimen Inc. (0001558569) (Filer)
- SECiSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Regulation FD Disclosure, Financial Statements and Exhibits8-K - iSpecimen Inc. (0001558569) (Filer)
- PRiSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI ProductsNew Agentic AI tools for protein discovery and disease trend prediction take iSpecimen beyond its biospecimen marketplaceWoburn, Massachusetts--(Newsfile Corp. - November 5, 2026) - iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace connecting scientists who need biospecimens for medical research with a network of healthcare specimen providers, today announced that it completed, on November 2, 2026, the acquisition of two artificial intelligence products from Foldlab AI Ltd. ("Foldlab"), a British Columbia company: an AI agent that identifies disease-associated proteins and an AI model that predicts and monitors disease trends.The transaction marks iSp
- SECiSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - iSpecimen Inc. (0001558569) (Filer)
- SECSEC Form PRE 14A filed by iSpecimen Inc.PRE 14A - iSpecimen Inc. (0001558569) (Filer)
- PRiSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI AgentWoburn, Massachusetts--(Newsfile Corp. - October 29, 2026) - iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), a provider of human biospecimens, today announced expanded access to fully consented, prospectively collected healthy donor whole blood through an existing collection partner.The expanded capability gives researchers a streamlined option for sourcing whole blood collected specifically for research. Specimens are generally shipped directly from the collection site on the day of collection, which is intended to enable next-day delivery to researchers.The program is designed to support a range of research needs, with donor eligibility criteria, associated data, and collectio
- SECSEC Form DEFR14A filed by iSpecimen Inc.DEFR14A - iSpecimen Inc. (0001558569) (Filer)
- SECSEC Form PRER14A filed by iSpecimen Inc.PRER14A - iSpecimen Inc. (0001558569) (Filer)
- SECSEC Form 8-K filed by iSpecimen Inc.8-K - iSpecimen Inc. (0001558569) (Filer)
- PRiSpecimen Supports Hospital Validation of New Chemistry AnalyzerCompany coordinates collection of more than 1,700 human specimens to support new laboratory testing capabilitiesWoburn, Massachusetts--(Newsfile Corp. - September 29, 2026) - iSpecimen, a provider of human biospecimens, is supporting a hospital laboratory in the validation of a new chemistry analyzer for clinical use. For the project, iSpecimen identified a healthcare system already using the same analyzer and is coordinating the collection of more than 1,700 serum, plasma, cerebrospinal fluid (CSF), and urine specimens for use in the hospital's validation process.The specimens represent a broad range of analytes and testing results, enabling the hospital to evaluate the analyzer's performan
- SECSEC Form DEF 14A filed by iSpecimen Inc.DEF 14A - iSpecimen Inc. (0001558569) (Filer)
- SECiSpecimen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - iSpecimen Inc. (0001558569) (Filer)
- SECiSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - iSpecimen Inc. (0001558569) (Filer)
- SECSEC Form PRE 14A filed by iSpecimen Inc.PRE 14A - iSpecimen Inc. (0001558569) (Filer)
- SECiSpecimen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - iSpecimen Inc. (0001558569) (Filer)
- PRiSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three WeeksWoburn, MA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- iSpecimen, a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline. Through its network of healthcare and research partners, iSpecimen coordinated the sourcing and collection of the required specimens and managed international fulfillment to meet the project's timeline. iSpecimen maintains a global and domestic network of healthcare institutions, laboratories, biobanks,
- SECiSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - iSpecimen Inc. (0001558569) (Filer)
- SECSEC Form 10-Q filed by iSpecimen Inc.10-Q - iSpecimen Inc. (0001558569) (Filer)
- SECiSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits8-K - iSpecimen Inc. (0001558569) (Filer)
- SECiSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - iSpecimen Inc. (0001558569) (Filer)
- PRiSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded WarrantsWOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of an aggregate of 996,231 shares of the Company’s common stock and pre-funded warrants to purchase up to an aggregate of 2,849,923 shares of common stock, for an aggregate purchase price of approximately $5.0 million. The Company intends to use the proceeds of the offering for repayment of outstanding liabilities, potential acquisitions of assets or investments in
- PRE.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimenNEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), a leading investment banking and financial advisory firm, today announced that it served as the exclusive placement agent in connection with the $5 million public offering for iSpecimen Inc. (NASDAQ:ISPC), an online global marketplace that connects researchers requiring biospecimens for medical research with a network of healthcare specimen providers. The offering provides iSpecimen with additional capital to support its strategic priorities, including repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, and general corporate purposes. The transaction marks E.F.
- SECSEC Form 424B4 filed by iSpecimen Inc.424B4 - iSpecimen Inc. (0001558569) (Filer)
- PRiSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded WarrantsWOBURN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of its public offering of approximately $5 million of the Company’s common stock, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $1.30 per share (or $1.2999 per pre-funded warrant, which is equal to the public offering price per share minus the $0.0001 per share exercise price of each pre-funded warrant). The Company intends to use the proceeds of the offering for
- SECSEC Form EFFECT filed by iSpecimen Inc.EFFECT - iSpecimen Inc. (0001558569) (Filer)
ISPC FAQ
10 questionsWhat is the latest news on ISPC?
In the last 30 days Quantisnow tracked 7 wire items for ISPC: 4 SEC filings, 2 press releases and news items and 1 M&A update. The most recent was published on November 9, 2026.What is ISPC revenue?
iSpecimen Inc. (ISPC) reported $466.3K of revenue for the twelve months ended Jun 30, 2026. That is down 92.1% from the year before. Revenue for fiscal 2025 was $1.93M.Is ISPC profitable?
No. iSpecimen Inc. reported a net loss of $11.42M for the twelve months ended Jun 30, 2026.How much cash and debt does ISPC have?
iSpecimen Inc. reported $4.41M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ISPC stock trade?
iSpecimen Inc. (ISPC) is listed on NASDAQ.What sector and industry is ISPC in?
iSpecimen Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.When did iSpecimen Inc. go public?
iSpecimen Inc. (ISPC) completed its IPO in 2021.What are analysts saying about ISPC?
iSpecimen Inc. has had 2 recent analyst actions on file. The most recent action was from Craig-Hallum: Buy with a $20.00 price target on 2022-01-04. Recent price targets range from $12.00 to $20.00.What companies are similar to ISPC?
Notable peers in the same industry include INCY (Incyte Corp.), CRL (Charles River Laboratories International Inc.), NRC (NRC Health), ICLR (ICON plc), OABI (OmniAb Inc.). Compare ISPC side-by-side with any of them on Quantisnow.How can I track ISPC on Quantisnow?
Quantisnow aggregates iSpecimen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ISPC to receive live email and push alerts on every new disclosure.